Journal of Endocrinological Investigation

, Volume 34, Issue 1, pp 78–84 | Cite as

Environmental triggers of thyroiditis: Hepatitis C and interferon-α

Review Article
First Online:

Abstract

Autoimmune thyroid diseases (AITD) are postulated to develop as a result of a complex interplay between several genetic and environmental influences. The pathogenesis of AITD is still not clearly defined. However, among the implicated triggers (e.g. iodine, infections, medications), more recent data confirmed strong associations of AITD with the hepatitis C virus (HCV) infection and interferon-α (IFNα) therapy. Moreover, it is likely that HCV and IFN act in synergism to trigger AITD in patients. Indeed, approximately 40% of HCV patients develop either clinical or subclinical disease while receiving IFNα. Interferon induced thyroiditis (IIT) can manifest as non-autoimmune thyroiditis (presenting as destructive thyroiditis, or non-autoimmune hypothyroidism), or autoimmune thyroiditis [presenting with clinical features of Graves’ disease (GD) or Hashimoto’s thyroiditis (HT)]. Although not yet clearly understood, it is thought that IFNα can induce thyroiditis via both immune stimulatory and direct toxic effects on the thyroid. In view of the high frequency of IIT, routine screening and surveillance of HCV patients receiving IFNα is recommended to avoid the complications, such as cardiac arrhythmias, associated with thyrotoxicosis. In summary, IIT is a common clinical problem that can be readily diagnosed with routine thyroid function screening of HCV patients receiving IFN. The treatment of IIT consists of the standard therapy for differing clinical manifestations of IIT such as GD, HT, or destructive thyroiditis. However, anti-thyroid medications are not recommended in this setting since they can potentially be hepatotoxic.

Keywords

Autoimmunity hepatitis C infection interferon thyroiditis 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Huber A, Menconi F, Corathers S, Jacobson EM, Tomer Y. Joint genetic susceptibility to type 1 diabetes and autoimmune thyroiditis: from epidemiology to mechanisms. Endocr Rev 2008, 29: 697–725.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Brix TH, Kyvik KO, Christensen K, Hegedus L. Evidence for a major role of heredity in Graves’ disease: a population-based study of two Danish twin cohorts. J Clin Endocrinol Metab 2001, 86: 930–4.PubMedGoogle Scholar
  3. 3.
    Rose NR, Bonita R, Burek CL Iodine: an environmental trigger of thyroiditis. Autoimmun Rev 2002, 1: 97–103.PubMedCrossRefGoogle Scholar
  4. 4.
    Li HS, Jiang HY, Carayanniotis G. Modifying effects of iodine on the immunogenicity of thyroglobulin peptides. J Autoimmun 2007, 28: 171–6.PubMedCrossRefGoogle Scholar
  5. 5.
    Oppenheim Y, Ban Y, Tomer Y. Interferon induced Autoimmune Thyroid Disease (AITD): a model for human autoimmunity. Autoimmun Rev 2004, 3: 388–93.PubMedCrossRefGoogle Scholar
  6. 6.
    Tomer Y, Davies TF. Infections and autoimmune endocrine disease. Baillieres Clin Endocrinol Metab 1995, 9: 47–70.PubMedCrossRefGoogle Scholar
  7. 7.
    Tomer Y, Huber A. The etiology of autoimmune thyroid disease: a story of genes and environment. J Autoimmun 2009, 32: 231–9.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Tomer Y, Blackard JT, Akeno N. Interferon alpha treatment and thyroid dysfunction. Endocrinol Metab Clin North Am 2007, 36: 1051–66.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Burek CL, Talor MV. Environmental triggers of autoimmune thyroiditis. J Autoimmun 2009, 33: 183–9.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Bahn AK, Mills JL, Snyder PJ, et al. Hypothyroidism in workers exposed to polybrominated biphenyls. N Engl J Med 1980, 302: 31–3.PubMedCrossRefGoogle Scholar
  11. 11.
    Desailloud R, Hober D. Viruses and thyroiditis: an update. Virol J 2009, 6: 5.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Deutsch M, Dourakis S, Manesis EK, et al. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy. Hepatology 1997, 26: 206–10.PubMedCrossRefGoogle Scholar
  13. 13.
    Tomer Y, Davies TF. Searching for the autoimmune thyroid disease susceptibility genes: From gene mapping to gene function. Endocr Rev 2003, 24: 694–717.PubMedCrossRefGoogle Scholar
  14. 14.
    Mandac JC, Chaudhry S, Sherman KE, Tomer Y. The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. Hepatology 2006, 43: 661–672.PubMedCrossRefGoogle Scholar
  15. 15.
    Dalgard O, Bjoro K, Hellum K, et al. Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy. J Intern Med 2002, 251: 400–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Prummel MF, Laurberg P. Interferon-alpha and autoimmune thyroid disease. Thyroid 2003, 13: 547–51.PubMedCrossRefGoogle Scholar
  17. 17.
    Grossman CJ, Roselle GA, Mendenhall CL Sex steroid regulation of autoimmunity. J Steroid Biochem Mol Biol 1991, 40: 649–59.PubMedCrossRefGoogle Scholar
  18. 18.
    Tomer Y, Menconi F, Davies TF, et al. Dissecting genetic heterogeneity in autoimmune thyroid diseases by subset analysis. J Autoimmun 2007, 29: 69–77.PubMedCrossRefGoogle Scholar
  19. 19.
    Ban Y, Tozaki T, Tobe T, et al. The regulatory T cell gene FOXP3 and genetic susceptibility to thyroid autoimmunity: An association analysis in Caucasian and Japanese cohorts. J Autoimmun 2007, 28: 201–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Ban Y, Greenberg DA, Davies TF, Jacobson E, Concepcion E, Tomer Y. Linkage analysis of thyroid antibody production: evidence for shared susceptibility to clinical autoimmune thyroid disease. J Clin Endocrinol Metab 2008, 93: 3589–96.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Vanderpump MP, Tunbridge WM, French JM, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf) 1995. 43: 55–6Google Scholar
  22. 22.
    Roti E, Minelli R, Giuberti T, et al. Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. Am J Med 1996, 101: 482–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Oppenheim Y, Kim G, Ban Y, et al. The effects of alpha interferon on the development of autoimmune thyroiditis in the NOD H2h4 mouse. Clin Dev Immunol 2003, 10: 161–5.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Jacobson EM, Huber A, Tomer Y. The HLA gene complex in thyroid autoimmunity: From epidemiology to etiology. J Autoimmun 2008, 30: 58–62.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Jacobson EM, Tomer Y. The CD40, CTLA-4, thyroglobulin, TSH receptor, and PTPN22 gene quintet and its contribution to thyroid autoimmunity: Back to the future. J Autoimmun 2007, 28: 85–98.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Kakizaki S, Takagi H, Murakami M, Takayama H, Mori M. HLA antigens in patients with interferon-alpha-induced autoimmune thyroid disorders in chronic hepatitis C. J Hepatol 1999, 30: 794–800.PubMedCrossRefGoogle Scholar
  27. 27.
    Kryczka W, Brojer E, Kowalska A, Zarebska-Michaluk D. Thyroid gland dysfunctions during antiviral therapy of chronic hepatitis C. Med Sci Monit 2001, 7 (Suppl 1): 221–5.PubMedGoogle Scholar
  28. 28.
    Jacobson EM, Chaudhry S, Mandac JC, Concepcion E, Tomer Y. Immune-regulatory gene involvement in the etiology of interferon induced thyroiditis (IIT). Thyroid 2006, 16: 926 (Meeting Abstract).Google Scholar
  29. 29.
    Tomer Y, Villanueva R. Hepatitis C and thyroid autoimmunity: is there a link? Am J Med 2004, 117: 60–69Google Scholar
  30. 30.
    Antonelli A, Ferri C, Pampana A, et al. Thyroid disorders in chronic hepatitis C. Am J Med 2004, 117: 10–3.PubMedCrossRefGoogle Scholar
  31. 31.
    Huang MJ, Tsai SL, Huang BY, Sheen IS, Yeh CT, Liaw YF. Prevalence and significance of thyroid autoantibodies in patients with chronic hepatitis C virus infection: a prospective controlled study. Clin Endocrinol (Oxf) 1999, 50: 503–9.CrossRefGoogle Scholar
  32. 32.
    Floreani A, Betterle C, Carderi I, Presotto F, Pedini B, Moscon A et al. Is hepatitis C virus a risk factor for thyroid autoimmunity? J Viral Hepat 2006, 13: 272–7.PubMedCrossRefGoogle Scholar
  33. 33.
    Ganne-Carrie N, Medini A, Coderc E, et al. Latent autoimmune thyroiditis in untreated patients with HCV chronic hepatitis: a case-control study. J Autoimmun 2000, 14: 189–93.PubMedCrossRefGoogle Scholar
  34. 34.
    Andrade LJ, Atta AM, D’Almeida Junior A, Paraná R. Thyroid dysfunction in hepatitis C individuals treated with interferon-alpha and ribavirin—a review. Braz J Infect Dis 2008, 12: 144–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Ward DL, Bing-You RG. Autoimmune thyroid dysfunction induced by interferon-alpha treatment for chronic hepatitis C: screening and monitoring recommendations. Endocr Pract 2001, 7: 52–8.PubMedCrossRefGoogle Scholar
  36. 36.
    Antonelli A, Ferri C, Fallahi P, et al. Thyroid disorders in chronic hepatitis C virus infection. Thyroid 2006, 16: 563–72.PubMedCrossRefGoogle Scholar
  37. 37.
    Hsieh MC, Yu ML, Chuang WL, et al. Virologic factors related to interferon-alpha-induced thyroid dysfunction in patients with chronic hepatitis C. Eur J Endocrinol 2000, 142: 431–7.PubMedCrossRefGoogle Scholar
  38. 38.
    Bartolome J, Rodriguez-Inigo E, Quadros P, et al. Detection of hepatitis C virus in thyroid tissue from patients with chronic HCV infection. J Med Virol 2008, 80: 1588–94.PubMedCrossRefGoogle Scholar
  39. 39.
    Akeno N, Blackard JT, Tomer Y. HCV E2 protein binds directly to thyroid cells and induces IL-8 production: a new mechanism for HCV induced thyroid autoimmunity. J Autoimmun 2008, 31: 339–44.PubMedCentralPubMedCrossRefGoogle Scholar
  40. 40.
    Tomer Y, Menconi F. Interferon induced thyroiditis. Best Pract Res Clin Endocrinol Metab 2009, 23: 703–12.PubMedCentralPubMedCrossRefGoogle Scholar
  41. 41.
    Pfeffer LM, Dinarello CA, Herberman RB, et al. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res 1998, 58: 2489–99.PubMedGoogle Scholar
  42. 42.
    Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347: 975–82.PubMedCrossRefGoogle Scholar
  43. 43.
    Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology 2003, 124: 1711–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Negro F. Adverse effects of drugs in the treatment of viral hepatitis. Best Pract Res Clin Gastroenterol 2010, 24: 183–92.PubMedCrossRefGoogle Scholar
  45. 45.
    Caraccio N, Giannini R, Cuccato S, Faviana P, Berti P, Galleri D et al. Type I interferons modulate the expression of thyroid peroxidase, sodium/iodide symporter, and thyroglobulin genes in primary human thyrocyte cultures. J Clin Endocrinol Metab 2005, 90: 1156–62.PubMedCrossRefGoogle Scholar
  46. 46.
    Caraccio N, Cuccato S, Pratesi F, Dardano A, Ursino S, Chimenti D et al. Effect of type I interferon(s) on cell viability and apoptosis in primary human thyrocyte cultures. Thyroid 2009, 19: 149–55.PubMedCrossRefGoogle Scholar
  47. 47.
    Chung RT, Gale M Jr, Polyak SJ, Lemon SM, Liang TJ, Hoofnagle JH. Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop. Hepatology 2008, 47: 306–20.PubMedCentralPubMedCrossRefGoogle Scholar
  48. 48.
    Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005, 436: 967–72.PubMedCrossRefGoogle Scholar
  49. 49.
    Corssmit EP, de Metz J, Sauerwein HP, Romijn JA. Biologic responses to IFN-alpha administration in humans. J Interferon Cytokine Res 2000, 20: 1039–47.PubMedCrossRefGoogle Scholar
  50. 50.
    You X, Teng W, Shan Z. Expression of ICAM-1, B7.1 and TPO on human thyrocytes induced by IFN-alpha. Chin Med J (Engl) 1999, 112: 61–6.Google Scholar
  51. 51.
    Ajjan RA, Watson PF, McIntosh RS, Weetman AP. Intrathyroidal cytokine gene expression in Hashimoto’s thyroiditis. Clin Exp Immunol 1996, 105: 523–8.PubMedCentralPubMedCrossRefGoogle Scholar
  52. 52.
    Todd I, Pujol-Borrell R, Hammond LJ, Bottazzo GF, Feldmann M. Interferon-gamma induces HLA-DR expression by thyroid epithelium. Clin Exp Immunol 1985, 61: 265–73.PubMedCentralPubMedGoogle Scholar
  53. 53.
    Farrar JD, Murphy KM. Type I interferons and T helper development. Immunol Today 2000, 21: 484–9.PubMedCrossRefGoogle Scholar
  54. 54.
    Carella C, Amato G, Biondi B, et al. Longitudinal study of antibodies against thyroid in patients undergoing interferon-alpha therapy for HCV chronic hepatitis. Horm Res 1995, 44: 110–4.PubMedCrossRefGoogle Scholar
  55. 55.
    Land KJ, Moll JS, Kaplan MH, Seetharamaiah GS. Signal transducer and activator of transcription (Stat)-6-dependent, but not Stat4-dependent, immunity is required for the development of autoimmunity in Graves’ hyperthyroidism. Endocrinology 2004, 145: 3724–30.PubMedCrossRefGoogle Scholar
  56. 56.
    Mazziotti G, Sorvillo F, Piscopo M, et al. Innate and acquired immune system in patients developing interferon-alpha-related autoimmune thyroiditis: a prospective study. J Clin Endocrinol Metab 2005, 90: 4138–44.PubMedCrossRefGoogle Scholar
  57. 57.
    Nagayama Y, Mizuguchi H, Hayakawa T, Niwa M, McLachlan SM, Rapoport B. Prevention of autoantibody-mediated Graves’-like hyperthyroidism in mice with IL-4, a Th2 cytokine. J Immunol 2003, 170: 3522–7.PubMedCrossRefGoogle Scholar
  58. 58.
    Corssmit EP, Heijligenberg R, Hack CE, Endert E, Sauerwein HP, Romijn JA. Effects of interferon-alpha (IFN-alpha) administration on leucocytes in healthy humans. Clin Exp Immunol 1997, 107: 359–63.PubMedCentralPubMedCrossRefGoogle Scholar
  59. 59.
    Krause I, Valesini G, Scrivo R, Shoenfeld Y. Autoimmune aspects of cytokine and anticytokine therapies. Am J Med 2003, 115: 390–7.PubMedCrossRefGoogle Scholar
  60. 60.
    Lindahl P, Leary P, Gresser I. Enhancement by interferon of the expression of surface antigens on murine leukemia L 1210 cells. Proc Natl Acad Sci U S A 1973, 70: 2785–8.PubMedCentralPubMedCrossRefGoogle Scholar
  61. 61.
    Akeno N, Tomer Y. Dissecting the mechanisms of interferon induced thyroiditis (IIT): Direct effects of interferon alpha on thyroid epithelial cells. The 89th Meeting of the Endocrine Society, Toronto, Canada, June 2007.Google Scholar
  62. 62.
    Fentiman IS, Thomas BS, Balkwill FR, Rubens RD, Hayward JL Primary hypothyroidism associated with interferon therapy of breast cancer. Lancet 1985, 1: 1166.PubMedCrossRefGoogle Scholar
  63. 63.
    Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002, 87: 489–99.PubMedCrossRefGoogle Scholar
  64. 64.
    Imagawa A, Itoh N, Hanafusa T, et al. Autoimmune endocrine disease induced by recombinant interferon-alpha therapy for chronic active type C hepatitis. J Clin Endocrinol Metab 1995, 80: 922–6.PubMedGoogle Scholar
  65. 65.
    Watanabe U, Hashimoto E, Hisamitsu T, Obata H, Hayashi N. The risk factor for development of thyroid disease during interferon-alpha therapy for chronic hepatitis C. Am J Gastroenterol 1994, 89: 399–403.PubMedGoogle Scholar
  66. 66.
    Preziati D, La Rosa L, Covini G, et al. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur J Endocrinol 1995, 132: 587–93.PubMedCrossRefGoogle Scholar
  67. 67.
    Carella C, Amato G, Biondi B et al. Longitudinal study of antibodies against thyroid in patients undergoing interferon-alpha therapy for HCV chronic hepatitis. Horm Res 1995, 44: 110–4.PubMedCrossRefGoogle Scholar
  68. 68.
    Marazuela M, Garcia-Buey L, Gonzalez-Fernandez B, et al. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy. Clin Endocrinol (Oxf) 1996, 44: 635–42.CrossRefGoogle Scholar
  69. 69.
    Carella C, Mazziotti G, Morisco F, et al. Long-term outcome of interferon-alpha-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment. J Clin Endocrinol Metab 2001, 86: 1925–9.PubMedGoogle Scholar
  70. 70.
    Martocchia A, Labbadia G, Paoletti V, et al. Hashimoto’s disease during interferon-alpha therapy in a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease. Neuro Endocrinol Lett 2001, 22: 49–52.PubMedGoogle Scholar
  71. 71.
    Baudin E, Marcellin P, Pouteau M, et al. Reversibility of thyroid dysfunction induced by recombinant alpha interferon in chronic hepatitis C. Clin Endocrinol (Oxf) 1993, 39: 657–61.CrossRefGoogle Scholar
  72. 72.
    Koh LK, Greenspan FS, Yeo PP. Interferon-alpha induced thyroid dysfunction: three clinical presentations and a review of the literature. Thyroid 1997, 7: 891–6.PubMedCrossRefGoogle Scholar
  73. 73.
    Wong V, Fu AX, George J, Cheung NW. Thyrotoxicosis induced by alpha-interferon therapy in chronic viral hepatitis. Clin Endocrinol (Oxf) 2002, 56: 793–8.CrossRefGoogle Scholar
  74. 74.
    Lisker-Melman M, Di Bisceglie AM, Usala SJ, Weintraub B, Murray LM, Hoofnagle JH. Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology 1992, 102: 2155–60.PubMedGoogle Scholar
  75. 75.
    Carella C, Mazziotti G, Amato G, Braverman LE, Roti E. Clinical review 169: Interferon-alpha-related thyroid disease: pathophysiological, epidemiological, and clinical aspects. J Clin Endocrinol Metab 2004, 89: 3656–61.PubMedCrossRefGoogle Scholar
  76. 76.
    Tran HA. The swinging thyroid in hepatitis C infection and interferon therapy. QJM 2010, 103: 187–91.PubMedCrossRefGoogle Scholar
  77. 77.
    Bohbot NL, Young J, Orgiazzi J, et al. Interferon-alpha-induced hyperthyroidism: a three-stage evolution from silent thyroiditis towards Graves’ disease. Eur J Endocrinol 2006, 154: 367–72.PubMedCrossRefGoogle Scholar
  78. 78.
    Antonelli A, Ferri C, Fallahi P. Hepatitis C: thyroid dysfunction in patients with hepatitis C on IFN-alpha therapy. Nat Rev Gastroenterol Hepatol 2009, 6: 633–5.PubMedCrossRefGoogle Scholar
  79. 79.
    Cadwell K, Patel KK, Maloney NS, et al. Virus-plus-susceptibility gene interaction determines Crohn’s disease gene Atg16L1 phenotypes in intestine. Cell 2010, 141: 1135–45.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2011

Authors and Affiliations

  1. 1.Division of Endocrinology, Department of MedicineMount Sinai Medical CenterNew York, NYUSA
  2. 2.James J. Peters VA Medical CenterNew York, NYUSA

Personalised recommendations